| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 138, 37-51, Copyright © 1991 by American Society for Investigative Pathology
REGULAR ARTICLES |
JR Merwin, W Newman, LD Beall, A Tucker and J Madri
Department of Pathology, Yale University, New Haven, Connecticut.
Transforming growth factor beta 1 (TGF-beta 1) and beta 2 (TGF-beta 2) are equipotent in many cell systems studies thus far. Recent data, however, show different effects elicited by these two growth factors in specific biologic systems. This investigation compares the effects of TGF-beta 1 and TGF-beta 2 bovine aortic endothelial cells (BAECs), rat epididymal fat pad microvascular endothelium (RFCs), and bovine aortic smooth muscle cells (BASCs). In two-dimensional cultures, proliferation of BAECs, BASMCs, and RFCs were all inhibited by TGF-beta 1, while in response to TGF-beta 2, BASMCs were fully inhibited, RFCs were modestly inhibited, and BAECs were unaffected. Bovine aortic endothelial cell migration was significantly inhibited by TGF-beta 1, but only slightly inhibited by TGF-beta 2. In contrast, BASMC migration was enhanced by TGF-beta 1 and was not affected by TGF-beta 2. In three-dimensional cultures, RFCs were stimulated to undergo in vitro angiogenesis in response to TGF-beta 1 and TGF-beta 2 at 10-fold higher concentrations. Three distinct receptor assays demonstrated the presence of type I and type II TGF-beta 1 cell-surface-binding proteins on BAECs, BASMCs, and RFCs. Labeled TGF-beta 1 was competed off completely with 100-fold molar excess unlabeled TGF-beta 1, but only partially with equivalent excess unlabeled TGF-beta 2. Furthermore the ratios of type I to type II TGF-beta receptors in these three vascular cell types vary from 1:1 in BAECs to 1.5:1 in RFCs to 3:1 in BASMCs and can be correlated with the differences noted in cellular responses to TGF-beta 1 and TGF-beta 2 in proliferation, migration, and in vitro angiogenic assays. These findings support the hypothesis that there are different responses to the TGF-beta s, depending on the cell type and experimental conditions as well as the TGF-beta concentration and isoform used.
This article has been cited by other articles:
 |
|
 |
|
  P. Durani, N. Occleston, S. O'Kane, and M. W. J. Ferguson Avotermin: A Novel Antiscarring Agent International Journal of Lower Extremity Wounds, September 1, 2008; 7(3): 160 - 168. [Abstract] [PDF]
|
|
|
|
 |
|
 Y. H. Lee, U. S. Kayyali, A. M. Sousa, T. Rajan, R. J. Lechleider, and R. M. Day Transforming Growth Factor-beta1 Effects on Endothelial Monolayer Permeability Involve Focal Adhesion Kinase/Src Am. J. Respir. Cell Mol. Biol., October 1, 2007; 37(4): 485 - 493. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. T. Gerthoffer Mechanisms of Vascular Smooth Muscle Cell Migration Circ. Res., March 16, 2007; 100(5): 607 - 621. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Lebrin, M. Deckers, P. Bertolino, and P. ten Dijke TGF-{beta} receptor function in the endothelium Cardiovasc Res, February 15, 2005; 65(3): 599 - 608. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. C. Carvalho, L. Jonker, M.-J. Goumans, J. Larsson, P. Bouwman, S. Karlsson, P. t. Dijke, H. M. Arthur, and C. L. Mummery Defective paracrine signalling by TGF{beta} in yolk sac vasculature of endoglin mutant mice: a paradigm for hereditary haemorrhagic telangiectasia Development, December 15, 2004; 131(24): 6237 - 6247. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Corallini, L. Possati, C. Trabanelli, E. Giraudo, R. Rocchetti, S. Talevi, A. Caputo, F. Bussolino, and G. Barbanti-Brodano Tumor-host interaction mediates the regression of BK virus-induced vascular tumors in mice: involvement of transforming growth factor-{beta}1 Carcinogenesis, September 1, 2003; 24(9): 1435 - 1444. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Furumatsu, Z. N. Shen, A. Kawai, K. Nishida, H. Manabe, T. Oohashi, H. Inoue, and Y. Ninomiya Vascular Endothelial Growth Factor Principally Acts as the Main Angiogenic Factor in the Early Stage of Human Osteoblastogenesis J. Biochem., May 1, 2003; 133(5): 633 - 639. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. J. Howat, S. T. Holgate, and P. M. Lackie TGF-beta isoform release and activation during in vitro bronchial epithelial wound repair Am J Physiol Lung Cell Mol Physiol, January 1, 2002; 282(1): L115 - L123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Liu, T.-Y. Ling, H.-S. Shieh, F. E. Johnson, J. S. Huang, and S. S. Huang Identification of the High Affinity Binding Site in Transforming Growth Factor-beta Involved in Complex Formation with alpha 2-Macroglobulin. IMPLICATIONS REGARDING THE MOLECULAR MECHANISMS OF COMPLEX FORMATION BETWEEN alpha 2-MACROGLOBULIN AND GROWTH FACTORS, CYTOKINES, AND HORMONES J. Biol. Chem., November 30, 2001; 276(49): 46212 - 46218. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Huang, M. Zhou, F. E. Johnson, H.-S. Shieh, and J. S. Huang An Active Site of Transforming Growth Factor-beta 1 for Growth Inhibition and Stimulation J. Biol. Chem., September 24, 1999; 274(39): 27754 - 27758. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Harris-White, T. Chu, Z. Balverde, J. J. Sigel, K. C. Flanders, and S. A. Frautschy Effects of Transforming Growth Factor-beta (Isoforms 1-3) on Amyloid-beta Deposition, Inflammation, and Cell Targeting in Organotypic Hippocampal Slice Cultures J. Neurosci., December 15, 1998; 18(24): 10366 - 10374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. W. Qian, J. K. Burmester, M. L.-S. Tsang, J. A. Weatherbee, A. P. Hinck, D. J. Ohlsen, M. B. Sporn, and A. B. Roberts Binding Affinity of Transforming Growth Factor-beta for Its Type II Receptor Is Determined by the C-terminal Region of the Molecule J. Biol. Chem., November 29, 1996; 271(48): 30656 - 30662. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. R. Dover and A. W. Valley Review : Angiogenesis: A new target for antineoplastic therapy Journal of Oncology Pharmacy Practice, January 1, 1996; 2(1): 43 - 60. [Abstract] [PDF]
|
|
|
|
|
|
S. Sankar, N. Mahooti-Brooks, M. Centrella, T. L. McCarthy, and J. A. Madri Expression of Transforming Growth Factor Type III Receptor in Vascular Endothelial Cells Increases Their Responsiveness to Transforming Growth Factor [IMAGE]2 J. Biol. Chem., June 2, 1995; 270(22): 13567 - 13572. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Dickson, J. Martin, F. Cousins, A. Kulkarni, S Karlsson, and R. Akhurst Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice Development, January 6, 1995; 121(6): 1845 - 1854. [Abstract] [PDF]
|
|
|
|
 |
|
 M Shah, D. Foreman, and M. Ferguson Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring J. Cell Sci., January 3, 1995; 108(3): 985 - 1002. [Abstract] [PDF]
|
|
|
|
|
|
M Shah, D. Foreman, and M. Ferguson Neutralising antibody to TGF-beta 1,2 reduces cutaneous scarring in adult rodents J. Cell Sci., January 5, 1994; 107(5): 1137 - 1157. [Abstract] [PDF]
|
|
|
|
|
|
E. Arciniegas, A. B. Sutton, T. D. Allen, and A. M. Schor Transforming growth factor beta 1 promotes the differentiation of endothelial cells into smooth muscle-like cells in vitro J. Cell Sci., October 1, 1992; 103(2): 521 - 529. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Papetti and I. M. Herman Mechanisms of normal and tumor-derived angiogenesis Am J Physiol Cell Physiol, May 1, 2002; 282(5): C947 - C970. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
